These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 22298228)
21. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Goldman LS; Genel M; Bezman RJ; Slanetz PJ JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570 [TBL] [Abstract][Full Text] [Related]
22. Drugs for ADHD. Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670 [No Abstract] [Full Text] [Related]
31. [Medication for ADHD and the risk of cardiovascular mortality]. Langendijk PN; Wilde AA Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941 [TBL] [Abstract][Full Text] [Related]
32. Drug treatment of ADHD - tenuous scientific basis. Vogt H; Lunde C Tidsskr Nor Laegeforen; 2018 Jan; 138(2):. PubMed ID: 29357653 [No Abstract] [Full Text] [Related]
33. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Greenhill LL; Pliszka S; Dulcan MK; Bernet W; Arnold V; Beitchman J; Benson RS; Bukstein O; Kinlan J; McClellan J; Rue D; Shaw JA; Stock S; J Am Acad Child Adolesc Psychiatry; 2002 Feb; 41(2 Suppl):26S-49S. PubMed ID: 11833633 [TBL] [Abstract][Full Text] [Related]
34. Encouraging news about ADHD drugs and heart risk in adults. Harv Ment Health Lett; 2012 Mar; 28(9):7. PubMed ID: 22474711 [No Abstract] [Full Text] [Related]
35. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update. Awudu GA; Besag FM Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483 [TBL] [Abstract][Full Text] [Related]
36. Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects. Golmirzaei J; Mahboobi H; Yazdanparast M; Mushtaq G; Kamal MA; Hamzei E Curr Pharm Des; 2016; 22(5):590-4. PubMed ID: 26601963 [TBL] [Abstract][Full Text] [Related]
37. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335 [TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390 [TBL] [Abstract][Full Text] [Related]
39. Trends in Stimulant Medication Use in Commercially Insured Youths and Adults, 2010-2014. Burcu M; Zito JM; Metcalfe L; Underwood H; Safer DJ JAMA Psychiatry; 2016 Sep; 73(9):992-3. PubMed ID: 27331629 [No Abstract] [Full Text] [Related]